X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs GSK PHARMA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA GSK PHARMA SANOFI INDIA/
GSK PHARMA
 
P/E (TTM) x 33.0 64.4 51.3% View Chart
P/BV x 6.3 10.3 60.8% View Chart
Dividend Yield % 1.4 1.2 117.2%  

Financials

 SANOFI INDIA   GSK PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
GSK PHARMA
Mar-17
SANOFI INDIA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs4,5603,838 118.8%   
Low Rs4,4002,637 166.9%   
Sales per share (Unadj.) Rs1,028.5354.2 290.4%  
Earnings per share (Unadj.) Rs129.039.8 324.3%  
Cash flow per share (Unadj.) Rs186.042.9 433.8%  
Dividends per share (Unadj.) Rs68.0030.00 226.7%  
Dividend yield (eoy) %1.50.9 163.8%  
Book value per share (Unadj.) Rs753.6236.9 318.1%  
Shares outstanding (eoy) m23.0384.70 27.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.49.1 47.7%   
Avg P/E ratio x34.781.4 42.7%  
P/CF ratio (eoy) x24.175.5 31.9%  
Price / Book Value ratio x5.913.7 43.5%  
Dividend payout %52.775.4 69.9%   
Avg Mkt Cap Rs m103,174274,216 37.6%   
No. of employees `0003.64.7 77.1%   
Total wages/salary Rs m3,5924,830 74.4%   
Avg. sales/employee Rs Th6,537.76,387.0 102.4%   
Avg. wages/employee Rs Th991.41,028.3 96.4%   
Avg. net profit/employee Rs Th819.8717.1 114.3%   
INCOME DATA
Net Sales Rs m23,68630,000 79.0%  
Other income Rs m708728 97.2%   
Total revenues Rs m24,39430,728 79.4%   
Gross profit Rs m5,2814,190 126.0%  
Depreciation Rs m1,313263 499.2%   
Interest Rs m150-   
Profit before tax Rs m4,6614,655 100.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m1,6911,744 97.0%   
Profit after tax Rs m2,9703,368 88.2%  
Gross profit margin %22.314.0 159.6%  
Effective tax rate %36.337.5 96.8%   
Net profit margin %12.511.2 111.7%  
BALANCE SHEET DATA
Current assets Rs m15,67316,742 93.6%   
Current liabilities Rs m6,6787,202 92.7%   
Net working cap to sales %38.031.8 119.4%  
Current ratio x2.32.3 101.0%  
Inventory Days Days7652 146.7%  
Debtors Days Days2221 107.4%  
Net fixed assets Rs m8,0988,635 93.8%   
Share capital Rs m230847 27.2%   
"Free" reserves Rs m17,08819,222 88.9%   
Net worth Rs m17,35620,069 86.5%   
Long term debt Rs m010 0.0%   
Total assets Rs m25,40030,038 84.6%  
Interest coverage x311.7NM-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.91.0 93.4%   
Return on assets %11.811.2 104.8%  
Return on equity %17.116.8 102.0%  
Return on capital %26.925.5 105.8%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,145528 1,353.2%   
Fx outflow Rs m6,8467,193 95.2%   
Net fx Rs m299-6,665 -4.5%   
CASH FLOW
From Operations Rs m3,2262,360 136.7%  
From Investments Rs m-1,5553,008 -51.7%  
From Financial Activity Rs m-1,818-5,108 35.6%  
Net Cashflow Rs m-147260 -56.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 50.7 119.1%  
Indian inst/Mut Fund % 14.4 10.2 141.2%  
FIIs % 14.6 23.8 61.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 15.4 68.2%  
Shareholders   15,184 102,036 14.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  TTK HEALTHCARE  ALKEM LABORATORIES  DIVIS LABORATORIES  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Hits 36,000-Mark; Infosys & Tata Steel Top Gainers(09:30 am)

Asian equities are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.82% while the Hang Seng is up 1.26%. The Nikkei 225 is trading up by 0.93%.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jan 23, 2018 11:03 AM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - ALEMBIC PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS